We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Netscientific Plc | LSE:NSCI | London | Ordinary Share | GB00BN4R5Q82 | ORD 5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 63.00 | 61.00 | 65.00 | 63.00 | 63.00 | 63.00 | 904 | 07:40:09 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 1M | -3.09M | -0.1312 | -4.80 | 14.85M |
From Apr 2019 to Apr 2024
By Adria Calatayud
Shares in NetScientific PLC (NSCI.LN) rose Thursday after it said portfolio company PDS Biotechnology Corp. (PDSB) will collaborate with U.S. drug maker Merck & Co. Inc. (MRK) in a phase II clinical trial.
NetScientific, a London-based healthcare technology company, said the trial will study PDS's lead product, PDS0101, in combination with Merck's cancer drug Keytruda as a first line treatment in patients with recurrent or metastatic head and neck cancer and high-risk human papillomavirus-16 infection.
Shares in NetScientific at 1256 GMT were up 40% at 8.75 pence.
Write to Adria Calatayud at adria.calatayudvaello@dowjones.com
(END) Dow Jones Newswires
October 03, 2019 09:13 ET (13:13 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Netscientific Chart |
1 Month Netscientific Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
